Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devin B Lowe

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Journal of Virology|November 6, 2009
Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phaseDevin B Lowe, Michael H Shearer, Cynthia A Jumper, et al.
Seminars in Cancer Biology|February 12, 2022
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunityTrevor S Anderson, Amanda L Wooster, Savanna L Piersall, et al.
Journal of Virology|November 17, 2006
Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastasesDevin B Lowe, Michael H Shearer, Cynthia A Jumper, et al.
Melanoma Research|November 9, 2020
Antibody-drug conjugates: an evolving approach for melanoma treatmentTrevor S Anderson, Amanda L Wooster, Ninh M La-Beck, et al.
Pharmacotherapy|October 27, 2015
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer TherapyNinh M La-Beck, Gary W Jean, Cindy Huynh, et al.
Pharmacological Research|December 21, 2020
Dendritic cell vaccine therapy for colorectal cancerAmanda L Wooster, Lydia H Girgis, Hayley Brazeale, et al.
Journal of Virology|July 30, 2010
Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigenDevin B Lowe, Michael H Shearer, Joel F Aldrich, et al.
Cancer Immunology, Immunotherapy : CII|May 25, 2004
Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunityRonald C Kennedy, Michael H Shearer, Devin B Lowe, et al.
Oncoimmunology|April 16, 2014
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanomaDevin B Lowe, Anamika Bose, Jennifer L Taylor, et al.
Clinical & Developmental Immunology|October 12, 2010
Vaccines and immunotherapeutics for the treatment of malignant diseaseJoel F Aldrich, Devin B Lowe, Michael H Shearer, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Virology|November 6, 2009
Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phaseDevin B Lowe, Michael H Shearer, Cynthia A Jumper, et al.
Seminars in Cancer Biology|February 12, 2022
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunityTrevor S Anderson, Amanda L Wooster, Savanna L Piersall, et al.
Journal of Virology|November 17, 2006
Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastasesDevin B Lowe, Michael H Shearer, Cynthia A Jumper, et al.
Melanoma Research|November 9, 2020
Antibody-drug conjugates: an evolving approach for melanoma treatmentTrevor S Anderson, Amanda L Wooster, Ninh M La-Beck, et al.
Pharmacotherapy|October 27, 2015
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer TherapyNinh M La-Beck, Gary W Jean, Cindy Huynh, et al.
Pharmacological Research|December 21, 2020
Dendritic cell vaccine therapy for colorectal cancerAmanda L Wooster, Lydia H Girgis, Hayley Brazeale, et al.
Journal of Virology|July 30, 2010
Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigenDevin B Lowe, Michael H Shearer, Joel F Aldrich, et al.
Cancer Immunology, Immunotherapy : CII|May 25, 2004
Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunityRonald C Kennedy, Michael H Shearer, Devin B Lowe, et al.
Oncoimmunology|April 16, 2014
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanomaDevin B Lowe, Anamika Bose, Jennifer L Taylor, et al.
Clinical & Developmental Immunology|October 12, 2010
Vaccines and immunotherapeutics for the treatment of malignant diseaseJoel F Aldrich, Devin B Lowe, Michael H Shearer, et al.
Pageof 4